Published in J Exp Med on February 01, 1999
Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci (2006) 2.85
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol (2000) 2.33
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 2.15
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Induction of proinflammatory cytokines and C-reactive protein in human macrophage cell line U937 exposed to air pollution particulates. Environ Health Perspect (2005) 1.50
A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum (2005) 1.36
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut (2006) 1.24
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
Molecular and cellular mechanisms of ectodomain shedding. Anat Rec (Hoboken) (2010) 1.08
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol (2012) 0.98
The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress Chaperones (2010) 0.97
Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J Immunol (2008) 0.96
Association between combined interleukin-6 and C-reactive protein levels and pulmonary function in older women: results from the Women's Health and Aging Studies I and II. J Am Geriatr Soc (2011) 0.88
Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med (2010) 0.86
Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses. J Virol (2013) 0.84
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT Pharmacometrics Syst Pharmacol (2014) 0.81
Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy. Jpn J Ophthalmol (2007) 0.80
Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque. Clin Exp Immunol (2006) 0.78
Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation. Mediators Inflamm (2016) 0.77
The mediating role of cytokine IL-6 on the relationship of FEV₁ upon 6-minute walk distance in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.77
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther (2015) 0.77
Molecular regulation of hepatocyte generation in adult animals. Am J Pathol (2002) 0.76
Possible potentiation by certain antioxidants of the anti-inflammatory effects of diclofenac in rats. ScientificWorldJournal (2014) 0.75
Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. PLoS One (2016) 0.75
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest (1998) 4.77
Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 4.19
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 3.15
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem (1996) 2.19
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 2.05
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol (1992) 1.99
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol (1995) 1.61
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun (1988) 1.55
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol (1995) 1.44
Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol (1994) 1.41
Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut (1995) 1.31
Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest (1997) 1.28
C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res (1997) 1.18
Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J Immunol (1989) 1.15
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol (1998) 1.07
Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest (1997) 1.07
Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol (1996) 1.06
Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A (1996) 1.02
Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol (1998) 0.98
Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci (1989) 0.98
Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med (1996) 0.96
Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol (1993) 0.96
Peptides generated from C-reactive protein by a neutrophil membrane protease. Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J Immunol (1990) 0.95
Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J Lab Clin Med (1990) 0.95
Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol (1996) 0.95
Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma (1991) 0.95
Tumor necrosis factor-alpha and interleukin-6 selectively regulate neutrophil function in vitro. J Surg Res (1995) 0.89
Interleukin-6 stimulates neutrophil production of platelet-activating factor. J Leukoc Biol (1996) 0.87
Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J Leukoc Biol (1996) 0.87
Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol (1996) 0.86
Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int J Hematol (1997) 0.86
The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. Int Immunol (1996) 0.84
Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol (1995) 0.83
Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. J Immunol (1997) 0.78
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Immunofluorescence of mitotic spindles by using monospecific antibody against bovine brain tubulin. Science (1975) 4.63
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Microarray fabrication with covalent attachment of DNA using bubble jet technology. Nat Biotechnol (2000) 3.38
Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science (1982) 3.37
A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut (2004) 3.35
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem (1990) 2.99
Modulation of insulin activities by leptin. Science (1996) 2.92
The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J (2001) 2.78
Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int (2007) 2.64
The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl (2003) 2.63
Nucleotide sequence of the PR-1 gene of Nicotiana tabacum. FEBS Lett (1987) 2.53
Tumor promoter, TPA, enhances replication of HTLV-III/LAV. Virology (1986) 2.51
Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A (1994) 2.49
Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol (1986) 2.40
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26
Mechanisms determining aerobic or anaerobic growth in the facultative anaerobe Salmonella typhimurium. Proc Natl Acad Sci U S A (1985) 2.25
Corticotropin-releasing activity of monokines. Science (1985) 2.24
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med (1997) 2.09
Classification and Structural Comparison of Full-Length cDNAs for Pathogenesis-Related Proteins. Plant Physiol (1987) 2.06
Increase of maximum life-span in Sweden, 1861-1999. Science (2000) 2.04
HTLV-II in patients with HTLV-I-associated myelopathy. Lancet (1991) 2.04
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol (1998) 2.00
Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein. Ann N Y Acad Sci (1983) 1.99
Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology (1988) 1.96
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A (1992) 1.89
Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res (1999) 1.88
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 1.86
Analysis of early and late Epstein-Barr virus associated polypeptides by immunoprecipitation. Virology (1979) 1.85
Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother (1987) 1.82
Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology (1995) 1.77
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75
Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood (1999) 1.73
Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS (1991) 1.73
Rectangularization revisited: variability of age at death within human populations. Demography (1999) 1.73
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1.70
Size-resolved emission rates of airborne bacteria and fungi in an occupied classroom. Indoor Air (2012) 1.69
Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci U S A (1990) 1.68
Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci (1995) 1.68
Identification and partial characterization of hepatocyte-stimulating factor from leukemia cell lines: comparison with interleukin 1. Proc Natl Acad Sci U S A (1985) 1.68
Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother (1986) 1.66
N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry (1996) 1.63
Evidence of vascular growth associated with laser treatment of normal canine myocardium. Ann Thorac Surg (1998) 1.63
Hepatitis C virus RNA in saliva. Lancet (1990) 1.62
Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X. J Virol (1997) 1.61
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand (2008) 1.59
Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18. Neurology (2004) 1.57
A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J Theor Biol (1986) 1.54
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol (2009) 1.54
[Intracranial physiological calcification on computed tomography (Part 2): Calcification in the choroid plexus of the lateral ventricles]. No To Shinkei (1988) 1.53
Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett (1996) 1.53
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol (1998) 1.51
beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest (1993) 1.51
Two simple programs for the analysis of data from enzyme-linked immunosorbent (ELISA) assays on a programmable desk-top calculator. Anal Biochem (1981) 1.49
Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol (1999) 1.48
Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha. AIDS Res Hum Retroviruses (1989) 1.48
Probable salmonella endocarditis treated with prosthetic valve replacement: a case report. Surgery (1974) 1.48
Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. Exp Neurol (2001) 1.45
Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus. J Rheumatol (2001) 1.45
Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron (1999) 1.45
Proteins of ribosome-bearing and free-membrane domains in Bacillus subtilis. J Bacteriol (1983) 1.45
Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Chem Pharm Bull (Tokyo) (1995) 1.44
Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. Proc Natl Acad Sci U S A (1990) 1.44
In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology (1993) 1.43
Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport (1995) 1.43
An in vitro bioassay for leukocytic endogenous mediator(s) using cultured rat hepatocytes. Inflammation (1981) 1.43
Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events. Virology (1985) 1.43
Structure and control of assembly of cytoplasmic microtubules in normal and transformed cells. J Supramol Struct (1976) 1.42
Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med (2001) 1.42
Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. Endoscopy (2012) 1.41
Ventricular echo beats and retrograde atrioventricular nodal exits in the dog heart: multiplicity in their electrophysiologic and anatomic characteristics. J Cardiovasc Electrophysiol (2001) 1.41
Transcription factor expression and Notch-dependent regulation of neural progenitors in the adult rat spinal cord. J Neurosci (2001) 1.41
Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol (1994) 1.41
Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res (1999) 1.41
Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med (2000) 1.40
Epidemiological survey of Orientia tsutsugamushi distribution in field rodents in Saitama Prefecture, Japan, and discovery of a new type. Microbiol Immunol (2001) 1.40
An infectious DNA clone of HIV type 1 subtype C. AIDS Res Hum Retroviruses (1999) 1.40
Assessment of transmyocardial perfusion in alligator hearts. Circulation (1997) 1.39
Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virol (1989) 1.39
Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br (2005) 1.38
Er81 is expressed in a subpopulation of layer 5 neurons in rodent and primate neocortices. Neuroscience (2005) 1.37
Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol (2000) 1.37
Evidence of increased dopamine receptor signaling in food-restricted rats. Neuroscience (2003) 1.37
Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol (1991) 1.37
Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem (1997) 1.35
Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci (1995) 1.35